Option chain shows key data for Carl Zeiss Meditec's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Carl Zeiss Meditec.

Carl Zeiss Meditec (OTC:CZMWY) Stock, Option Chain

CARL ZEISS MEDITEC

Carl Zeiss Meditec is one of the largest medical technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.

Analyst Color

Long Ideas

News

Short Ideas

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

CZMWY

Innovation and digitalization have been in focus among ophthalmology majors.

Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: &#39;Innovation Is Key&#39;

Emerging Markets

Small Cap

Markets

TOPCF

Vision is the most cherished of the five senses. Losing your eyesight can have a tremendously debilitating impact on your day-to-day life.

24% of American Dont Have Vision Care: Here&#39;s Why

Tech

Image provided by Retina Technologies

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Technology That Could Catch Vision Problems Early And Save Your Eyesight?

CARL ZEISS MEDI UNSP/ADR by Carl Zeiss Meditec AG

Carl Zeiss Meditec AG

Carl Zeiss: We've Seen Outperformance, But I See More Upside Potential

Carl Zeiss Meditec AG goes ex dividend tomorrow

Carl Zeiss Meditec AG (CZMWF) Q2 2024 Earnings Call Transcript

Carl Zeiss Meditec: Slightly Better Valuation, Still A Significant Upside

Carl Zeiss Meditec AG (CZMWF) Q3 2024 Earnings Call Transcript

Invesco International Diversified Fund Q2 2024 Review

Invesco International Small-Mid Company Fund Q2 2024 Review

Carl Zeiss: Significant Underperformance, Valuation At Multi-Year Lows

Janus Henderson European Focus Fund Q2 2024 Commentary

My 3 Favorite European Stocks To Diversify Your Portfolio

ALFVF

ALFVY

ASMIY

ASML

ASMLF

ASMXF

AZNCF

BRKR

CABGY

CABJF

CCDBF

CCLLF

CHHMF

CZMWF

DLMAF

DSGX

DSRLF

DTEGF

DTEGY

EPIAF

EPIPF

EPOKY

IFNNF

IFNNY

LDNXF

LNSTY

LVMHF

LVMUY

MPZAF

MPZAY

MSSMY

MSUXF

NCSYF

NICE

NONOF

NSRGF

NSRGY

NVSEF

OBIIF

PGPHF

RELX

RLXXF

RNKGF

RNMBF

RNMBY

SARTF

SAUHF

SAUHY

SDTHF

SOAGY

SPXSF

SPXSY

SSNLF

SSSGY

SUVPF

TCEHY

TCTZF

TSMWF

TTFNF

UMGNF

UNCFF

UNCRY

UNVGY

VACNY

VTTGF

VZIO

WMMVF

WMMVY

XINXF

YMATF

Press Releases

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market

ZEISS announces OCT technology enhancements to better support growing era of data-driven patient care

ZEISS innovation paves way to more personalized patient care with cutting-edge AI technology and industry-leading surgical solutions

ZEISS Redefines Disease Management and Treatment within the ZEISS Retina Workflow

ZEISS reinvents lens extraction with the first hand-held ultrasound-free lens removal device, available in the U.S.

ZEISS introduces its latest Robotic Visualisation System for neuro surgery

ZEISS expands ophthalmic offerings to improve patient care with new digital AI tools and revolutionary surgical solutions

Carl Zeiss Meditec

Comments

Carl Zeiss Meditec

Carl Zeiss Meditec (CZMWY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga